STAAR Surgical Co's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 52/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 24.97.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
STAAR Surgical Co's Score
Industry at a Glance
Industry Ranking
52 / 207
Overall Ranking
154 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Hold
Current Rating
24.969
Target Price
+6.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
STAAR Surgical Co Highlights
StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -11.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.83M shares, decreasing 23.09% quarter-over-quarter.
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Ticker SymbolSTAA
CompanySTAAR Surgical Co
CEOFarrell (Stephen C)
Websitehttps://www.staar.com/
FAQs
What is the current price of STAAR Surgical Co (STAA)?
The current price of STAAR Surgical Co (STAA) is 23.350.
What is the symbol of STAAR Surgical Co?
The ticker symbol of STAAR Surgical Co is STAA.
What is the 52-week high of STAAR Surgical Co?
The 52-week high of STAAR Surgical Co is 30.810.
What is the 52-week low of STAAR Surgical Co?
The 52-week low of STAAR Surgical Co is 13.500.
What is the market capitalization of STAAR Surgical Co?
The market capitalization of STAAR Surgical Co is 1.15B.
What is the net income of STAAR Surgical Co?
The net income of STAAR Surgical Co is -20.21M.
Is STAAR Surgical Co (STAA) currently rated as Buy, Hold, or Sell?
According to analysts, STAAR Surgical Co (STAA) has an overall rating of Hold, with a price target of 24.969.
What is the Earnings Per Share (EPS TTM) of STAAR Surgical Co (STAA)?
The Earnings Per Share (EPS TTM) of STAAR Surgical Co (STAA) is -1.952.